Immunome, Inc. · 2 days ago
Executive Director, Investor Relations and Corporate Communications
Bothell, WA
Full-time
Onsite
Director/Executive
$280K/yr - $320K/yr
10+ years expImmunome, Inc. is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. The Executive Director, Investor Relations will serve as the primary point of contact for the investment community and will play a critical role in shaping the company's external communications strategy.
BiopharmaBiotechnologyMedicalPharmaceutical
Responsibilities
Execute the investor relations program in partnership with the CEO and CFO, ensuring clear, consistent, and disciplined communication with the capital markets
Own day-to-day IR execution, including investor and analyst meeting coordination, targeting support, CRM management, feedback capture, and follow-up
Draft all core IR materials, including investor presentations, fact sheets, FAQs, earnings scripts, Q&A documents, and conference talk tracks
Serve as the primary point of contact for sell-side analysts on logistics and clarifications; proactively identify and correct misinterpretations
Coordinate investor conferences, non-deal roadshows, and other capital markets engagements
Track, synthesize, and report investor sentiment and market feedback to senior management and the Board
Lead execution of the corporate communications function, with direct responsibility for drafting press releases, corporate updates, pipeline and clinical announcements, and reactive statements
Translate complex scientific, clinical, and regulatory information into clear, accurate, and investable external messaging
Partner closely with Legal and senior management to ensure Reg FD compliance, disclosure discipline, and appropriate risk framing
Manage PR and IR agencies, setting direction and maintaining a high bar for accuracy, clarity, and quality
Support media engagement and spokesperson preparation; manage inbound media inquiries as needed
Ensure consistency across all external-facing materials and channels
Serve as the central point of coordination for external messaging across Finance, Clinical, Regulatory, Legal, and Business Development
Own the external communications calendar and disclosure cadence
Identify communication risks early and escalate judgment calls appropriately
Support special situations, including clinical data releases, financings, and issues management
Qualification
Required
A minimum of 10 years of experience in investor relations, corporate communications, or a closely related role within biotech, biopharma, or life sciences
Public company experience, including direct involvement in earnings preparation and material disclosures
Demonstrated ability to independently draft high-quality press releases, investor materials, and executive-level communications
Strong scientific literacy, with the ability to understand and accurately communicate clinical data and development strategy
Strong financial literacy and comfort engaging with analysts, investors, and capital markets topics
Experience working closely with senior executives and serving as a trusted execution partner
Experience managing external agencies (IR, PR, communications)
Bachelor's degree required; advanced degree a plus
Exceptional written and verbal communication skills, with a proven ability to translate complex scientific and financial information into clear, disciplined external messaging
Deep understanding of biotech sector dynamics and public equity markets
Sound judgment around disclosure, tone, timing, and risk; effective in high-stakes, fast-moving situations
Strong analytical, strategic thinking, and presentation skills
Ability to operate effectively in a fast-paced, high-growth environment while maintaining precision, professionalism, and confidentiality
Company
Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients.
51-200 employees
Funding
Current Stage
Public CompanyTotal Funding
$998.85MKey Investors
JPEO-CBRNDU.S. Department of DefenseRobin Hood Ventures
2025-12-16Post Ipo Equity· $400M
2025-01-29Post Ipo Equity· $150M
2024-02-13Post Ipo Equity· $230M
Leadership Team
Clay Siegall
President and CEO
Purnanand D. Sarma
President & CEO
Recent News
2026-01-09
BioWorld Financial Watch
2025-12-19
Company data provided by crunchbase